KRAS and renal carcinoma: Additionally, while a previous experimental study reported that spironolactone reduced proliferation of renal cancer cells by blocking the mineralocorticoid receptor and affecting K-RAS expression [17], this finding contradicts results from prior clinical observations [7, 10, 11] as well as our study.